MGK2— You suggested the piece was gonna be concise…

New Post Public Reply Private Reply Replies (1) Message Board
sherlock57 MGK_2 #151534
2,004
MGK2—

You suggested the piece was gonna be concise… so I read it.

680 words? To basically say what most of us already know? Coulda been done in half the words…

That’s the problem I have with most of your posts—and, apparently the posts you highlight—they gussy up what most of us on this board already know. And they are excessively wordy—which you alluded to in your introduction… so this wordy response is fair game, right?

You are talking to the converted… and most of us are very conversant/up-to-date with what’s going on with leronlimab. So the post might have been appropriate for newbies and those ignorant of leronlimab’s promise. But for this board—c’mon! Ya kinda belittle our awareness of the promise that this drug has…

Two specific problems I have with Tiny’s argument, and your highlighting the post:

In the comparison of leronlimab with Trodelvy, under Tumor Shrinkage we have “some complete responses; numbers coming at ESMO.” Under Complete Remissions we have “confirmed complete remissions; final count revealed at ESMO.” And for Median Survival we have “>50% alive at 12 months.” All promising… but when you base most of your argument on essentially “final numbers at ESMO,” well why not wait for ESMO? Aren’t you getting ahead of yourself? And we all know generalizing from incomplete evidence is worse than… incomplete evidence.

As far as the “real toxicity” that comes with Trodelvy,” well, 4 out of 10 coming down with neutropenia sounds pretty bad… Now I don’t have a medical degree… but let me decode my experience with chemo for you. I received oxaliplatin and capecitabine for Stage 3 locally advanced colon cancer in the spring/summer of 22 (after 10 inches of my lower colon was surgically removed). After three or four rounds of treatment I was told my bloodwork revealed neutropenia and was given a couple pre-filled syringes to shoot myself up with at home. Did a couple injections, more bloodwork. I was fine. No further problems. So the idea that neutropenia is “classic, brutal chemo” was certainly not my experience. And I wonder why Tiny highlighted neutropenia. I’d be more worried about the severe diarrhea… If it was anything like the glycol 3350 laxative I took for my colonoscopy-surgery, well, that was no fun even if it wasn’t unexpected or explosive!

So, I don’t want to make the same mistake as Tiny—generalizing from limited evidence. Maybe I should have been more worried about the neutropenia. (My oncologists didn’t make like it was a big deal… maybe he was being low-key just to spare me worry). But it certainly wasn’t brutal chemo. Perhaps some other medical professionals could weigh in?

Back in 22 I asked my oncologist about leronlimab… Of course he hadn’t heard about it. I would have taken it in a heartbeat! From all I’ve read since it would have been useful. Perhaps curative. The lack of serious adverse effects is one of leronlimabs greatest attributes…. Along with the promise of efficacy in both chronic and acute diseases. But we all know that!

No one is more bullish about leronlimab than yours truly. Bullish—I’m a fuckin Mastadon! But generalizing from incomplete evidence, and scaring people with chemo-fear… I really don’t get it. I trust the science. And we are not there yet. So close! And it’s hard to wait. Listen--I applaud Tiny’s and MGK2’s enthusiasm. But keep it in your pants. And don’t use science-talk to support unscientific conclusions. It is an insult to our collective intelligence. Even if it may make us feel good in the short run. And the danger in hyping this is not what we choose to believe about leronlimab—it’s what the medical pros believe. 45 minutes and a poster competing with some 400 other posters at a busy conference? I’ll wait for the CRC trial results and any further news about mTNBC before I wet myself. And when the share price begins to head north I'll let myself dream of the South Seas...

Of course any partnership news would rile me up too! And Pestell's conference talk in May could be the catalyst we have been waiting for. But at this point, anything less is just talk. And we all know... talk is cheap.

And MGK2—you have the research skills to really make a contribution. So stick with the science instead of the cheerleading.

—Sherlock—
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palatin Prepares for FY27 Results Amid Market Curiosity

Updated Category News Views 116

Mark Your Calendars, Investors! Folks grumble about the mundane task of checking fiscal calendars, but without this intel, where are we? On November 17, 2026, Palatin Technologies (NASDAQ:PTN) is slated to release their Q1 Fiscal Year 2027 operating results bright and early, before most of us have even sipped our coffee. The buzz around these numbers is as electric as any...

Continue Reading
Walmart Tops 2026 Recall List: 81 Notices, Food Issues Lead

Updated Category News Views 78

Walmart Behind 81 Recalls: Scrutinizing 2026's Top Contender For an outfit that prides itself on shaking up shopping carts coast to coast, Walmart's stumble onto the recall hotseat this year is a head-scratcher. Imagine leading with 81 official recalls—that's more than a flash in the pan, it's the whole frying pan catching fire. Target and Costco aren't slouches, but...

Continue Reading
The Melt Expands with Key Texas Franchise Deal

Updated Category News Views 83

Throwing Down the Gauntlet: The Melt Expands If there's one thing I've learned after decades watching these restaurant chains multiply like rabbits it’s this: when a veteran gets involved, you perk up. The Melt has done just that by roping in Syed Ahmad—a name that actually means something in this game—to open eight new locations in the Lone Star State. It isn't...

Continue Reading
BETR Investors Face Action: Nov. 20 Deadline Nears

Updated Category News Views 121

High Stakes for BETR Shareholders If you're holding shares in Better Home & Finance Holding Company, right now might feel like you're at a craps table with emptying pockets. BETR, trading under NASDAQ, has become the center of a legal hurricane, with investors eyeing the November 20th deadline to join a securities class action led by Hagens Berman. The class period in...

Continue Reading
Fly-E Faces Revenue Drop Amid Retail Restructuring

Updated Category News Views 153

Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...

Continue Reading
Data Center Transformers on the Brink of a Boom

Updated Category News Views 300

A Flash Look: Powering Up Data Centers Look, if you're thinking of sidestepping data center transformers as just another cog in the machine, think again. This market's set to balloon—doubling from $5.59 billion in 2026 to a jaw-dropping $10.72 billion by 2031. We're talking a chunky 13.9% CAGR. Not every bit of news grabs you by the lapels, but this one does. What’s...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 74

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 194

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
LEOTEK's AI Tech Shaping Smarter Cities at COP31

Updated Category News Views 103

AI-Powered Evolution in Urban Infrastructure Hang on to your hats, folks, 'cause LEOTEK is turning heads at COP31 with its AI-driven transformation of urban landscapes. As cities stretch at the seams to keep up with modern challenges, LEOTEK's got more than a few tricks up its sleeve with its trademark blend of traffic system intelligence and energy management prowess....

Continue Reading
YYForce Expands in UAE with Key Hospitality Wins

Updated Category News Views 170

Unveiling YYForce's Middle East Strategy Smack in the middle of an aggressive Middle Eastern expansion, YYForce (NASDAQ: YFOR) is making waves with some new headline-grabbing contracts in the UAE. This ain't just a side hustle—it's big time. They're planting their flag across the luxury hospitality sector like they're going for a moon landing. The recent announcement...

Continue Reading

Top 5 Most Recently Viewed Articles

Henning Cheese Excels with Top Awards at National Contest

Updated Category News Views 128

Henning Cheese Shines at the National Cheese Contest Henning Cheese has achieved remarkable recognition at the recent U.S. Championship Cheese Contest, where it secured multiple first-place awards and an impressive overall ranking. The company's standout entry, Onion & Chive Cheddar, once again placed within the top 20 overall, marking a significant achievement for the...

Continue Reading
Actelis Networks Introduces Innovative Cryptocurrency Strategy

Updated Category News Views 116

Actelis Networks Embraces Cryptocurrency for Treasury Management Actelis Networks, Inc. (NASDAQ: ASNS), based in Fremont, California, has taken an exciting step forward in its corporate strategy. The company, renowned for its market-leading cyber-hardened networking solutions for IoT and broadband applications, has announced an innovative treasury management strategy that...

Continue Reading
Nykredit Invest Balance Announces Trading Suspension with Key Details

Updated Category News Views 201

Nykredit Invest Balance Trading Suspension Nykredit Portefølje Administration A/S has made a significant decision by requesting Nasdaq Copenhagen to suspend trading in selected funds managed by their team. This step is essential as technical issues are currently preventing the correct calculation of the Net Asset Values (NAV) for these funds. Details of the Fund...

Continue Reading
European Wax Center Announces New Equity Grants for Employees

Updated Category News Views 179

Overview of European Wax Center's Inducement Grants European Wax Center, Inc. (NASDAQ: EWCZ), renowned for its exceptional out-of-home waxing services, has recently made a significant announcement regarding employee equity grants. This initiative aims to strengthen its position as a leading franchisor and operator in the industry. Effective from a noted date, the...

Continue Reading
Bread Financial Holdings: Navigating Challenges and Growth Ahead

Updated Category News Views 472

Understanding Bread Financial Holdings and Its Journey Bread Financial Holdings, Inc. (NYSE: BFH) is a significant entity in the U.S. consumer finance realm, facing a dynamic environment of regulatory obstacles and competitive landscapes. With an ongoing strategic shift, the company is attracting the attention of both analysts and investors as it seeks to carve a new path...

Continue Reading